Decision Resources and Millennium Research Group have produced a new report that finds that, despite recent media attention to Plavix problems, Bristol-Myers Squibb remains the number one cardiovascular drug company in the UA/NSTEMI market for surveyed physicians. The new Brands & Strategies report entitled Brands & Strategies: UA/NSTEMI finds that BMS has achieved this strong reputation despite generating the least amount of revenue among competitors from drug sales in UA/NSTEMI.

"BMS generates less revenue than other competitors because it only markets one drug, Plavix, in UA/NSTEMI and only markets this drug in the United States (Sanofi-Aventis markets Plavix outside the U.S.)," said Elena Rossi, analyst at Millennium Research Group. "However, because Plavix is a gold-standard therapy in UA/NSTEMI as well as other cardiovascular indications, BMS has established itself as the leading UA/NSTEMI company in the eyes of U.S. cardiologists."

About Brands & Strategies

Brands & Strategies is the first and only report series to bring together all of the competitive information elements biopharmaceutical companies need to make informed decisions about their products and best next-steps. Each report includes the following:

  -- Physician perceptions of companies and brands, sources of information,      opinion of future strategies and messaging, and impact of key events.   -- Brand-specific, event-driven, five-year annualized market forecast.   -- Country-specific market share projections by company and brand, with      impact of future events.   -- Drug class and brand versus generics sales by country.   -- Projected price for all drugs for five years, including generic pricing      impact on all drugs.   -- Overview of competitive landscape for disease.   -- Pipeline analysis by company within a specific disease.   -- SWOT analysis on each brand.   -- Analysis of brand-specific messaging.   -- Detailed brand and lifecycle strategy, including clinical trial reviews      and competitive analysis.   -- Selling strategies based on clinical trials.   -- Analysis of promotional spend for each product.    About Millennium Research Group 

Millennium Research Group (www.MRG.net), part of the Decision Resources, Inc., family, is a leading provider of strategic information to the healthcare sector. Focused on the medical device, pharmaceutical, and biotechnology industries, the company provides clients its specialized industry expertise through published reports and customized consulting services.

About Decision Resources

Decision Resources, Inc., (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Safety Concerns Over GlaxoSmithKline's Avandia and Takeda's Actos Open the Door for Rapid Uptake of Merck's Novel Agent Januvia

View Now